Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$400M |
| 2 |
Citigroup
C
|
+$395M |
| 3 |
CELG
Celgene Corp
CELG
|
+$360M |
| 4 |
Amazon
AMZN
|
+$347M |
| 5 |
RTX Corp
RTX
|
+$344M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$397M |
| 2 |
Salesforce
CRM
|
+$355M |
| 3 |
TSS
Total System Services, Inc.
TSS
|
+$354M |
| 4 |
ULTI
Ultimate Software Group Inc
ULTI
|
+$349M |
| 5 |
Autodesk
ADSK
|
+$313M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.61% |
| 2 | Financials | 4.93% |
| 3 | Healthcare | 4% |
| 4 | Consumer Discretionary | 3.82% |
| 5 | Industrials | 3.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8276
PUT
DHT Holdings
DHT
$3.14B
| $119K | ﹤0.01% |
20,100
-15,600
| -44% | -$85K |
|
8277
PUT
IDT Corp
IDT
$1.66B
| $119K | ﹤0.01% |
12,600
-10,000
| -44% | -$73.7K |
|
8278
PUT
Quad
QUAD
$513M
| $119K | ﹤0.01% |
15,000
-155,500
| -91% | -$1.63M |
|
|
SMC
8279
PUT
Summit Midstream
SMC
$482M
| $119K | ﹤0.01% |
1,067
-1,840
| -63% | -$224K |
|
|
KA
8280
DELISTED
Kineta, Inc. Common Stock
KA
| $119K | ﹤0.01% |
872
+222
| +34% | +$34.5K |
|
|
VSLR
8281
CALL
DELISTED
VIVINT SOLAR, INC.
VSLR
| $119K | ﹤0.01% |
16,300
-27,800
| -63% | -$176K |
|
|
SORL
8282
PUT
DELISTED
SORL Auto Parts, Inc.
SORL
| $119K | ﹤0.01% |
34,300
+8,600
| +33% | +$29.4K |
|
8283
Harvard Bioscience
HBIO
$30.3M
| $118K | ﹤0.01% |
+5,867
| New | +$172K |
|
|
NETI
8284
CALL
DELISTED
Eneti Inc.
NETI
| $118K | ﹤0.01% |
+2,755
| New | +$118K |
|
|
PTNR
8285
DELISTED
Partner Communications
PTNR
| $118K | ﹤0.01% |
28,081
-1,564
| -5% | -$6.94K |
|
|
ALDR
8286
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
| $118K | ﹤0.01% |
+10,000
| New | +$121K |
|
8287
PUT
Vuzix
VUZI
$258M
| $117K | ﹤0.01% |
28,700
-48,000
| -63% | -$137K |
|
|
AGEN
8288
CALL
Agenus
AGEN
$329M
| $116K | ﹤0.01% |
1,977
-117
| -6% | -$6.39K |
|
8289
Immersion
IMMR
$249M
| $116K | ﹤0.01% |
15,178
-56,005
| -79% | -$473K |
|
|
STR
8290
DELISTED
Sitio Royalties
STR
| $116K | ﹤0.01% |
+3,463
| New | +$114K |
|
8291
CALL
ADT
ADT
$5.47B
| $115K | ﹤0.01% |
18,800
-9,600
| -34% | -$61.1K |
|
8292
PUT
Pacific Biosciences
PACB
$357M
| $115K | ﹤0.01% |
+19,000
| New | +$133K |
|
|
ZAGG
8293
CALL
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
| $115K | ﹤0.01% |
16,500
+4,800
| +41% | +$36.1K |
|
8294
PUT
Anavex Life Sciences
AVXL
$298M
| $114K | ﹤0.01% |
33,800
+15,400
| +84% | +$47.8K |
|
8295
PUT
Karyopharm Therapeutics
KPTI
$45.8M
| $114K | ﹤0.01% |
1,273
-594
| -32% | -$47.7K |
|
|
TRVN
8296
DELISTED
Trevena, Inc.
TRVN
| $114K | ﹤0.01% |
178
+145
| +439% | +$119K |
|
|
NAK
8297
PUT
Northern Dynasty Minerals
NAK
$908M
| $113K | ﹤0.01% |
188,500
+6,600
| +4% | +$3.43K |
|
8298
CALL
Siebert Financial
SIEB
$78.9M
| $113K | ﹤0.01% |
12,600
+2,200
| +21% | +$21.9K |
|
|
SPPI
8299
CALL
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $113K | ﹤0.01% |
13,100
-4,200
| -24% | -$37.6K |
|
|
ZAGG
8300
PUT
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
| $113K | ﹤0.01% |
16,200
-16,300
| -50% | -$123K |
|
Similar funds
Ken Griffin's Q2 2019 Portfolio in Review
As of Q2 2019, Ken Griffin held 10,425 positions worth $218B, up 8.5% from $201B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Ken Griffin deployed $6.68B of net new capital in Q2 2019, opening 1,217 new positions and adding to 3,775 existing holdings. Its largest new stake was Uber: 7,077,910 shares worth $328M.
By sector, the portfolio is most concentrated in Technology at 5.6% of assets, down from 6% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Eli Lilly, an estimated $397M trimmed.
- Ken Griffin's largest Q2 2019 buy was Uber: 7,077,910 shares worth $328M.
- Ken Griffin added most to Netflix in Q2 2019, an estimated $400M increase.
- Ken Griffin's biggest Q2 2019 reduction was Eli Lilly, cutting an estimated $397M.
- Ken Griffin fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $349M.
- Ken Griffin's ten largest holdings make up 23% of its $218B portfolio in Q2 2019.
- Ken Griffin opened 1,217 new positions and closed 1,335 in Q2 2019.
- Ken Griffin's portfolio value rose 8.5% quarter-over-quarter to $218B.
Based on Citadel Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.